I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Azad, Arun A
240
results:
Search for persons
X
Format
Online (240)
Mediatypes
Articles (Online) (131)
Bookchapter (Online) (5)
OpenAccess-fulltext (104)
Sorted by: Relevance
Sorted by: Year
?
1
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatec..:
Eapen, Renu S.
;
Buteau, James P.
;
Jackson, Price
...
European Urology. 85 (2024) 3 - p. 217-226 , 2024
Link:
https://doi.org/10.1016/..
?
2
Precision medicine for prostate cancer: An international pe..:
Hamid, Anis A.
;
Sweeney, Christopher J.
;
Hovens, Christopher
..
Urologic Oncology: Seminars and Original Investigations. , 2024
Link:
https://doi.org/10.1016/..
?
3
Publisher Correction: First-line talazoparib with enzalutam..:
Fizazi, Karim
;
Azad, Arun A.
;
Matsubara, Nobuaki
...
Nature Medicine. 30 (2024) 5 - p. 1505-1505 , 2024
Link:
https://doi.org/10.1038/..
?
4
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel..:
Hofman, Michael S
;
Emmett, Louise
;
Sandhu, Shahneen
...
The Lancet Oncology. 25 (2024) 1 - p. 99-107 , 2024
Link:
https://doi.org/10.1016/..
?
5
Plain language summary of the results from the TALAPRO-2 st..:
Agarwal, Neeraj
;
Azad, Arun A
;
Carles, Joan
...
Future Oncology. , 2024
Link:
https://doi.org/10.1080/..
?
6
Role of FDG PET/CT in Management of Patients with Prostate ..:
Sutherland, Duncan E.K.
;
Azad, Arun A.
;
Murphy, Declan G.
...
Seminars in Nuclear Medicine. 54 (2024) 1 - p. 4-13 , 2024
Link:
https://doi.org/10.1053/..
?
7
Cost Effectiveness of Systemic Treatment Intensification fo..:
Sathianathen, Niranjan J.
;
Lawrentschuk, Nathan
;
Konety, Badrinath
...
European Urology Oncology. , 2023
Link:
https://doi.org/10.1016/..
?
8
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy pri..:
Ali, Muhammad
;
Wood, Simon
;
Pryor, David
...
Contemporary Clinical Trials Communications. 33 (2023) - p. 101145 , 2023
Link:
https://doi.org/10.1016/..
?
9
First-line talazoparib with enzalutamide in HRR-deficient m..:
Fizazi, Karim
;
Azad, Arun A.
;
Matsubara, Nobuaki
...
Nature Medicine. 30 (2023) 1 - p. 257-264 , 2023
Link:
https://doi.org/10.1038/..
?
10
Determinants of outcome following PSMA-based radioligand th..:
Kostos, Louise
;
Buteau, James P.
;
Hofman, Michael S.
.
Therapeutic Advances in Medical Oncology. 15 (2023) - p. 175883592311793 , 2023
Link:
https://doi.org/10.1177/..
?
11
Safety of Lutetium-177 prostate-specific membrane antigen-6..:
Sutherland, Duncan E. K.
;
Kashyap, Raghava
;
Jackson, Price
...
Therapeutic Advances in Medical Oncology. 15 (2023) - p. 175883592311770 , 2023
Link:
https://doi.org/10.1177/..
?
12
PCPro: a clinically accessible, circulating lipid biomarker..:
Scheinberg, Tahlia
;
Lin, Hui-Ming
;
Fitzpatrick, Michael
...
Prostate Cancer and Prostatic Diseases. 27 (2023) 1 - p. 136-143 , 2023
Link:
https://doi.org/10.1038/..
?
13
BRCA-deficient metastatic prostate cancer has an adverse pr..:
Fettke, Heidi
;
Dai, Chao
;
Kwan, Edmond M.
...
eBioMedicine. 95 (2023) - p. 104738 , 2023
Link:
https://doi.org/10.1016/..
?
14
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sen..:
Gomez-Veiga, Francisco
;
Szmulewitz, Russell Z.
;
Holzbeierlein, Jeffrey
...
European Urology Oncology. , 2023
Link:
https://doi.org/10.1016/..
?
15
Emergence of triplet therapy for metastatic castration-sens..:
Sathianathen, Niranjan J.
;
Pan, Henry Y.C.
;
Lawrentschuk, Nathan
...
Urologic Oncology: Seminars and Original Investigations. 41 (2023) 5 - p. 233-239 , 2023
Link:
https://doi.org/10.1016/..
1-15